You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,464,137

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,464,137

Title:	Glycoprotein
Abstract:	The invention relates to a composition comprising a glycoprotein comprising the Fc domain of an antibody, or a fragment thereof, comprising an Asn (asparagine) residue and an oligosaccharide structure attached thereto, wherein said oligosaccharide structure has a structure according to formula I; and wherein at least 20% of the oligosaccharide structures attached to glycoprotein in the composition consist of oligosaccharide structures according to formula (I).
Inventor(s):	Satomaa; Tero (Helsinki, FI), Saarinen; Juhani (Helsinki, FI), Natunen; Jari (Vantaa, FI), Vilkman; Anja (Klaukkala, FI), Virtanen; Heidi (Helsinki, FI), Hiltunen; Jukka (Helsinki, FI)
Assignee:	Glykos Finland Oy (Helsinki, FI)
Application Number:	14/365,022
Patent Claims:	1. A pharmaceutical composition comprising a glycoprotein comprising the Fc domain of an antibody, or a fragment thereof, comprising an Asn residue and an oligosaccharide structure attached thereto and a pharmaceutically acceptable carrier, wherein the oligosaccharide structure consists of the structure according to formula I ##STR00005## wherein (.beta.-N-Asn)=.beta.-N linkage to Asn; wherein at least 50% of the oligosaccharide structures attached to glycoprotein in the composition consist of oligosaccharide structures according to formula I. 2. The pharmaceutical composition according to claim 1, wherein at least 66.7% at least 90%, at least 95%, or at least 99% of the oligosaccharide structures attached to the glycoprotein in the composition consist of oligosaccharide structures according to formula I. 3. The pharmaceutical composition according to claim 1, wherein the Asn residue corresponds to Asn297 of human IgG wherein the numbering corresponds to the EU index as in Kabat. 4. The pharmaceutical composition according to claim 1, wherein the Fc domain is a human Fc domain. 5. The pharmaceutical composition according to claim 1, wherein the glycoprotein is a fusion protein comprising an Fc domain. 6. The pharmaceutical composition according to claim 1, wherein the glycoprotein is a human antibody, a humanized antibody or a chimeric antibody comprising a human Fc domain. 7. The pharmaceutical composition according to claim 1, wherein the glycoprotein is an IgG antibody. 8. The pharmaceutical composition according to claim 1, wherein the glycoprotein is an IgG1 antibody. 9. The pharmaceutical composition according to claim 1, wherein the glycoprotein is an antibody directed against human vascular endothelial growth factor (VEGF), epidermal growth factor receptor 1 (EGFR), tumor necrosis factor alpha (TNF-.alpha.), CD20, epidermal growth factor receptor 2 (HER2/neu), CD52, CD33, CD11a, glycoprotein IIb/IIIa, CD25, IgE, interleukin-2 (IL-2) receptor, or respiratory syncytial virus (RSV). 10. The pharmaceutical composition according to claim 1, wherein the glycoprotein is an antibody that is bevacizumab, tositumomab, etanercept, trastuzumab, adalimumab, alemtuzumab, gemtuzumab ozogamicin, efalizumumab, rituximab, infliximab, abciximab, baasiliximab, palivizumab, omalizumab, daclizumab, cetuximab, panitumumab, or ibritumomab tiuxetan.

Details for Patent 9,464,137

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994	⤷ Try a Trial	2031-12-13
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2031-12-13
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2031-12-13
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997	⤷ Try a Trial	2031-12-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.